Quanterix Corporation reported total revenues of $138.9 million for the fiscal year ended December 31, 2025, reflecting a slight increase of 1% compared to $137.4 million in 2024. The growth was primarily driven by a 17% increase in product revenue, which reached $92.9 million, largely attributed to the acquisition of Akoya Biosciences, Inc. This acquisition contributed $21.9 million to product revenue, although legacy Quanterix product sales decreased by 11% due to changing macroeconomic conditions. Service and other revenue, however, saw a decline of 14%, dropping to $44.2 million, primarily due to reduced demand from pharmaceutical customers and the completion of a significant agreement with Eli Lilly in 2024.
The company incurred a net loss of $107.2 million in 2025, a significant increase from the $38.5 million loss reported in 2024. This increase in losses was attributed to higher operating expenses, which rose by 40% to $190.5 million, driven by costs associated with the Akoya acquisition, including $16.4 million in non-recurring acquisition and integration costs. Research and development expenses also increased by 16% to $35.9 million, reflecting ongoing investments in product development and innovation.
Quanterix has made strategic moves to enhance its market position, including the acquisition of Akoya and Emission, Inc., which are expected to expand its capabilities in spatial biology and multiplex assays. The company submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test for Alzheimer’s disease, marking a significant step in its diagnostics strategy. Additionally, the Centers for Medicare & Medicaid Services approved a reimbursement rate of $897 for the LucentAD Complete multiplex test, which is anticipated to facilitate broader access to this diagnostic solution.
As of December 31, 2025, Quanterix had approximately 450 employees, with a significant portion dedicated to sales, marketing, and research and development. The company continues to focus on expanding its customer base and enhancing its product offerings, particularly in the neurology and oncology markets. Looking ahead, Quanterix aims to achieve cash flow breakeven in 2026, contingent on meeting revenue and expense objectives, while navigating the challenges posed by macroeconomic conditions and competition in the life sciences sector.
About Quanterix Corp
Quanterix is a life sciences company specializing in ultra-sensitive digital immunoassay platforms based on proprietary Simoa technology. Its core business involves developing and selling instruments, consumables, and assay kits for protein biomarker detection in blood and fluids, serving research, biotech, and clinical markets. The company advances early disease detection, diagnostics, and biomarker research, with applications in neurology, oncology, immunology, and inflammation.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.